Backgrounds Despite the genomic landscape of urothelial carcinomas (UC) patients,
especially those with UC of bladder (UCB), has been comprehensively delineated and …

Analyses of large transcriptomics data sets of muscle-invasive bladder cancer (MIBC) have
led to a consensus classification. Molecular subtypes of upper tract urothelial carcinomas …

Urothelial carcinoma is a highly heterogeneous disease that can arise throughout the entire
urothelial lining from the renal pelvis to the proximal urethra. Upper tract urothelial …

Background Different genomic characterization in urothelial carcinoma (UC) by site of origin
may imply contrasting therapeutic opportunities and pathogenetic mechanisms. The aim of …

Upper tract urothelial carcinoma (UTUC) is a rare malignancy, occurring in 5–10% of
patients diagnosed with UC, and involves the renal pelvis, calyces, or ureters. UTUC can be …

Urothelial carcinoma (UC) is the most frequent malignancy of the urinary tract, which
consists of bladder cancer (BC) for 90%, while 5% to 10%, of urinary tract UC (UTUC). BC …

The use of immunotherapy has revolutionized the management of patients with locally
advanced, unresectable, and metastatic urothelial carcinoma (UC); however, platinum …

Context Bladder urothelial carcinoma (BUC) and upper tract urothelial carcinoma (UTUC)
have genetic differences, which may influence therapy. Objective The aim of the current …

Background Upper urinary tract urothelial cancer (UTUC) may have unique etiologic and
genomic factors compared to bladder cancer. Objective To characterize the genomic …

Recent research in next-generation sequencing characterized the genomic landscape of
urothelial cancer. However, the majority of the studies focused on bladder cancer (BC) …